模型介绍
Large Language Models (LLMs) have demonstrated remarkable versatility in recent years, offering potential applications across specialized domains such as healthcare and medicine. Despite the availability of various open-source LLMs tailored for health contexts, adapting general-purpose LLMs to the medical domain presents significant challenges. In this paper, we introduce BioMistral, an open-source LLM tailored for the biomedical domain, utilizing Mistral as its foundation model and further pre-trained on PubMed Central. We conduct a comprehensive evaluation of BioMistral on a benchmark comprising 10 established medical question-answering (QA) tasks in English. We also explore lightweight models obtained through quantization and model merging approaches. Our results demonstrate BioMistral's superior performance compared to existing open-source medical models and its competitive edge against proprietary counterparts. Finally, to address the limited availability of data beyond English and to assess the multilingual generalization of medical LLMs, we automatically translated and evaluated this benchmark into 7 other languages. This marks the first large-scale multilingual evaluation of LLMs in the medical domain. Datasets, multilingual evaluation benchmarks, scripts, and all the models obtained during our experiments are freely released. **Advisory Notice!** Although BioMistral is intended to encapsulate medical knowledge sourced from high-quality evidence, it hasn't been tailored to effectively, safely, or suitably convey this knowledge within professional parameters for action. We advise refraining from utilizing BioMistral in medical contexts unless it undergoes thorough alignment with specific use cases and undergoes further testing, notably including randomized controlled trials in real-world medical environments. BioMistral 7B may possess inherent risks and biases that have not yet been thoroughly assessed. Additionally, the model's performance has not been evaluated in real-world clinical settings. Consequently, we recommend using BioMistral 7B strictly as a research tool and advise against deploying it in production environments for natural language generat
主要特点
特点摘要待依据来源补齐,不凭模型名称推断能力。
局限与注意事项
暂无足够来源支持具体缺点结论。请重点验证实际任务表现、时延、数据政策、许可与版本生命周期。
来源报价与费用分析
同一模型在不同渠道、地区和配置下可能采用不同价格。下表独立保留各渠道报价,不将渠道价格视为厂商官方统一价格。
| 来源 / 渠道 | 输入 | 输出 | 计费单位 | 采集时间 |
|---|---|---|---|---|
| 暂未取得可核验报价,请查阅来源渠道。 | ||||
按月估算基础 Token 费用
预估不包含缓存优惠、阶梯定价、多模态附加费用、网络检索、税费及推理额外输出。
公开评测与运行配置
暂无已采集的可核验公开评分。模型未上榜不代表能力较低。
查看完整已收录榜单 →常见问题
开放权重是否代表可以免费商用?
不一定。应核对具体版本许可证、商用门槛和使用政策。自部署还会产生算力和维护成本。
这些价格是实时结算价格吗?
不是实时结算价格,而是带采集时间的来源报价快照。请到对应渠道核对当前版本、区域、折扣和计费方式。
资料来源与可追溯记录
许可证:apache-2.0。模型介绍与第三方评测均以原来源的具体版本和方法为准。